President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
Trump said that the ability to purchase such plans would be “Very, very powerful for our nation and very good for a lot of people.” The order also includes provisions for the creation of health plans that will provide short-term, limited-duration coverage, and for exploration of how employers might use health reimbursement arrangements, which are plans that reimburse employees for medical expense paid for out of pocket.
Senator Rand Paul (R-Kentucky) said that “what I believe is the biggest free market reform of healthcare in a generation” that would “…allow millions of people to get insurance across state lines and at an inexpensive price.” Vice President Mike Pence also praised the executive order, saying that it was a “Critical step to lower the cost of health insurance for working Americans.”
While today’s executive order may not be the full repeal of the Affordable Care Act (ACA) that Republicans have promised their supporters, Trump made it clear that today’s effort was part of a larger push to overhaul healthcare: “I just keep hearing repeal, replace; repeal, replace. Well, we’re starting that process,” he said. “I believe we have the votes to do block grants” at a later time, he went on, apparently referring to a plan similar to the one proposed in the Graham-Cassidy healthcare reform bill that recently failed to garner enough support to move to a Senate vote.
Trump also suggested that the ACA individual market would continue to lose participation from insurers, predicting that half of all counties in the nation would have only 1 insurer participating in the ACA health insurance exchanges, and that others would have none. Allowing associations to purchase insurance plans across states would mean that “they will have so many options,” and that competition among plans would be “staggering.”
The president also indicated that the coming months would see his administration taking further measures related to healthcare and to the economy at large. These measures, he promised, would include “massive” tax cuts.
The Future of Biosimilar Gene Therapies: Key Issues and Potential
September 11th 2024While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
BioRationality: FDA Opens Up Biosimilar Inquiries on Reddit
August 26th 2024Sarfaraz K. Niazi, PhD, urges stakeholders to engage with the FDA on its Reddit forum—where a representative will answer complex biosimilar questions—encourages clearing misconceptions, and advocates for updates to the Biologics Price Competition and Innovation Act guidelines.